UNSPSC 51192014: Rasburicase

This classification denotes a uricosuric agent with the molecular formula C1521H2381N417O461S7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 08GY9K1EUO, more generally known as rasburicase. European Medicines Agency schedules rasburicase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04204MIG. The term RASBURICASE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, no. 1, 2000, list 43. Most nations schedule Rasburicase under HS 35079090 and SITC 51691.

SMILES:. As of Q4 2014, RASBURICASE remains the US FDA Preferred Term for this commodity.. Rasburicase bears US NLM identifiers UMLS ID C0937932 and NCI Concept Code C2404.

UNSPSC 51192014 Rasburicase is a Commodity code that describes a urate oxidase enzyme used to treat tumor lysis syndrome and hyperuricemia in patients undergoing chemotherapy; however, the recent state and local contract opportunities tagged under this code show no procurement activity aligned with pharmaceutical products or rasburicase itself. The three opportunities posted between March and June 2026 involve athletic training services for municipal fire and police departments, general medical aid supplies for fire rescue operations, and a request for information regarding direct-to-manufacturer prescription programs through a state health agency—none of which involve rasburicase or specialty pharmaceutical procurement. The mismatch between the code's nominal pharmaceutical scope and the actual work being solicited suggests that either the code has been misapplied to these opportunities or the recent activity does not reflect genuine rasburicase procurement activity at the state and local level.

The issuing bodies in the recent record span municipal fire services (City of Tucson, City of Tampa) and state health administration (Texas Health and Human Services Commission), with no repeat buyers or concentrated procurement pattern under this code. Geographic activity appears in Arizona, Florida, and Texas. The City of Tucson's RFP for athletic training services (due June 9, 2026) is the most recent substantive opportunity, but it involves certification and injury rehabilitation rather than pharmaceutical products. The City of Tampa's ITB for medical aid supplies (bid opening April 9, 2025) covers bandages, antiseptic sprays, and first aid items with a $100,000 department budget and set-asides for small local and minority-owned businesses. The Texas HHS RFI (response due April 3, 2026) addresses direct pharmaceutical contracting mechanisms but does not specify rasburicase or any specialty oncology drugs. No recent opportunities in the block reflect actual rasburicase procurement or specialty pharmaceutical vendor activity.